Compare HOTH & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOTH | CODX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 15.6M |
| IPO Year | 2019 | 2017 |
| Metric | HOTH | CODX |
|---|---|---|
| Price | $1.17 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.50 | $2.25 |
| AVG Volume (30 Days) | 219.2K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.23 |
| 52 Week High | $3.80 | $1.55 |
| Indicator | HOTH | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 46.20 |
| Support Level | $1.16 | $0.34 |
| Resistance Level | $1.25 | $0.41 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 52.96 | 22.21 |
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.